MedPath

Misoprostol+Oxytocin vs. Carbetocin in CS

Phase 2
Completed
Conditions
Cesarean Section
Interventions
Registration Number
NCT02786992
Lead Sponsor
Ain Shams University
Brief Summary

This prospective randomized double-blind clinical trial will be conducted at Ain-Shams University Maternity Hospital, Cairo, Egypt. Patients eligible for elective lower segment cesarean section will be randomized to 2 groups. Group 1: will receive 400 ug misoprostol following + 10 IU oxytocin intravenous slowly after cord clamping. Group 2: will receive 100 ug carbetocin intravenous after cord clamping.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
600
Inclusion Criteria
  • Women with singleton pregnancy Women scheduled for elective CS full term (gestational age ≥37 weeks).
Exclusion Criteria
  • hypersensitivity to oxytocin, carbetocin or prostaglandins
  • contraindication to prostaglandins (e.g. glaucoma)
  • history of significant heart disease
  • severe asthma
  • epilepsy
  • history or evidence of liver
  • renal or vascular disease
  • history of coagulopathy
  • thrombocytopenia or anticoagulant therapy
  • women with HELLP syndrome
  • eclampsia
  • women presenting by placental abruption
  • contraindication to spinal anesthesia as carbetocin is licensed for use with regional anesthesia only.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CarbetocinPlacebo100 ug Carbetocin IV
Misoprostol + OxytocinPlacebo400 ug sublingual misoprostol + 10 IU Oxytocin IVI
Misoprostol + OxytocinMisoprostol400 ug sublingual misoprostol + 10 IU Oxytocin IVI
Misoprostol + OxytocinOxytocin400 ug sublingual misoprostol + 10 IU Oxytocin IVI
CarbetocinCarbetocin100 ug Carbetocin IV
Primary Outcome Measures
NameTimeMethod
incidence of post-partum hemorrhage24 hours
amount of blood loss24 hours
Secondary Outcome Measures
NameTimeMethod
Number of participants with NICU admission24 hours
Number of participants needing extra uterotonic drug (10 IU oxytocin IVI)24 hours

An experienced attendant (principal investigator) will assess the need of extra uterotonic drug (10 IU oxytocin IVI) if the uterus is atonic or if blood loss is more than 1000 ml.

Number of participants needing hemostatic surgical interventionsintra-operative
Hemoglobin deficit in gm/dl24 hours

difference between pre-operative and 24 hours post-operative hemoglobin in gm/dl

APGAR score at 1 minute and 5 minutes1 minute and 5 minutes
Drug side effects24 hours
Time till resuming bowel habits24 hours

Time of passing gas will be recorded how many hours post-operative

hematocrit deficit in %24 hours

difference between pre-operative and 24 hours post-operative hematocrit in %

Trial Locations

Locations (1)

Ain Shams University Maternity Hospital

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath